NCI-MATCH Press Center

The materials posted in this section are a collection of press releases, announcements, news stories, and blogs about the NCI-MATCH trial. For media inquiries, send an email or call 215.789.3631.

Looking for a publication? Search and sort this NCI-MATCH Publications List.

August 05, 2024: Path to precision: Targeted cancer drugs go from table to trials to bedside (mentions NCI-MATCH) Ars Technica

June 13, 2024: Umbrella? Basket? Discover 4 Types of Adaptive Clinical Trials And Their Benefits (mentions NCI-MATCH) Clinical Leader

March 14, 2024: NCI-MATCH Analysis Suggests Dual HER2 Therapy Activity Beyond Breast, Gastric Cancer Precision Medicine Online

February 16, 2024: AACR’s Clinical Cancer Research publishes a review article, 'Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial'

December 01, 2023: AACR’s Clinical Cancer Research publishes a review article, 'The New NCI Precision Medicine Trials'

October 19, 2023: It’s a MATCH: Peter O’Dwyer on the Future of Precision Oncology Blog Post

September 27, 2023: Ray McDermott and Cancer Trials Ireland Podcast host Peter O’Dwyer for a ‘Learnings from NCI-MATCH’ conversation

September 25, 2023: NIH podcast features Peter O’Dwyer and Lyndsay Harris on the profound impacts of precision medicine and genomic sequencing on cancer care Cancer HealthCast

June 15, 2023: Nature Medicine publishes key lessons from NCI-MATCH to guide future precision medicine trials Media Advisory

May 8, 2023: NCI-MATCH named among five innovative oncology therapies changing the game MDLinx

October 26, 2022: NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib in Arm Z1K Press Release

August 16, 2022: NCI-MATCH precision medicine trial leads to FDA drug approval: Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600Emutation Blog Post

June 22, 2022: FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH OncLive

June 1, 2022: Precision medicine clinical trials: A conversation between Peter O’Dwyer and Lale Kostakoglu The Journal of Nuclear Medicine

April 15, 2022: NCI-MATCH: The Blueprint for Future Precision Medicine Trials. In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee of the Developmental Therapeutics Committee is offering expertise moving forward. Blog Post

April 11, 2022: As NCI-MATCH winds down, the cancer research community takes stock of lessons learned Precision Oncology News/GenomeWeb (requires free sign-up)

March 17, 2022: FDA notes the NCI-MATCH trial in its release of new guidance on master protocols and expansion cohorts Endpoints News (requires free sign-up)

March 17, 2022: NCI-MATCH umbrella trial adds arm for LAG-3 expressing, mismatch repair deficient cancers Precision Oncology News/GenomeWeb

March 16, 2022: ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations Press Release

July 14, 2021: Matchmakers: How Basket Trials Match Patients With Drugs Based on Their Tumors Cure Today

June 24, 2021: For patients with advanced or rare cancers, NCI-MATCH may offer a treatment option Blog Post

May 7, 2021: NCI-MATCH has 12 open arms awaiting patients with advanced or rare cancers, and is expanding with the opening of a new treatment arm Blog Post

April 27, 2021: The search for patients intensifies with the opening of a new NCI-MATCH treatment arm Blog Post

April 26, 2021: A new study arm opens in NCI-MATCH, expanding patients’ potential to qualify for this precision medicine cancer clinical trial when they may not have other options Press Release

January 11, 2021: Cancer Cell publishes a spotlight article, 'The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies'

October 19, 2020: A genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks Blog Post

October 16, 2020: Data from the NCI-MATCH precision medicine trial established a new benchmark for next-generation sequencing in clinical trials The Cancer Letter

October 14, 2020: NCI-MATCH data shows the value of platform trials for patients with rare genomically driven cancers. Interview with lead investigator Keith T. Flaherty, MD. Precision Oncology News/GenomeWeb

October 13, 2020: NCI-MATCH precision medicine cancer trial makes a major contribution to tumor gene testing for cancer treatment selection Journal of Clinical Oncology publishes molecular analysis of 6000 NCI-MATCH patients Press Release

August 13, 2020: In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report on Arm H. The combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAF V600>-mutated tumors outside of currently approved indications. OncLive

February 20, 2020: The results of Arm Z1D in the NCI-MATCH trial continue to attract media attention. Nilofer Azad, MD (Johns Hopkins) talks about the activity of nivolumab in MMR-deficient cancers in a feature article. MedPage Today/ASCO Reading Room

January 13, 2020: A series of changes were recently incorporated in Addendum #24 of the NCI-MATCH trial Blog Post

January 7, 2020: Jhaveri, MD, FACP (Memorial Sloan Kettering) is the primary author of the publication of NCI-MATCH Arm Q results, published in the Annals of Oncology. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors. Press Release

December 19, 2019: The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH. “The confirmed overall response rate for nivolumab in tumors with DNA mismatch repair deficiencies was 36%–or 15 of 42 patients with cancers other than colon,” says Nilofer Azad, MD (Johns Hopkins University). Press Release

June 3, 2019: Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations. “Arm H met its primary endpoint with an overall objective response rate of 33 percent,” said lead researcher April K. S. Salama, MD (Duke University). Press Release

November 12, 2018: NCI-MATCH precision medicine cancer trial enrolling 7-8 new patients weekly. Findings from Arm Y are to be presented at an international meeting. Press Release

June 4, 2018: NCI-MATCH (Molecular Analysis for Therapy Choice), the largest precision medicine trial of its kind, has achieved a milestone with the release of results of several treatment arms of the trial. The new results offer findings of interest for future cancer research that could ultimately play a role in bringing targeted treatments to patients with certain gene abnormalities. Press Release

May 30, 2018: NCI-MATCH (EAY131) achieves a milestone with the release of patient outcomes results from Arms I, Q, and W at the American Society of Clinical Oncology (ASCO) 2018 annual meeting Press Release

July 7, 2017: James Doroshow discusses how NCI-MATCH tests the ability to integrate next-generation sequencing The Cancer Letter

July 7, 2017: NCI-MATCH keeps enrolling. Targeted mutations are proving to be less common than estimated. The Cancer Letter

June 7, 2017: As the NCI-MATCH precision medicine cancer trial reaches its 6,000-patient tumor sequencing goal two years early, the trial continues with a new strategy to complete enrollment by casting a wider net for patients Press Release

September 26, 2016: ECOG-ACRIN opens the quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ today. COMET is an ancillary study to the NCI-MATCH (EAY131) trial, already underway. Press Release

August 16, 2016: The ECOG-ACRIN Cancer Research Group has received federal approval to add a quality-of-life research study, COMmunication and Education in Tumor Profiling (EAQ152) or ‘COMET’ to the NCI-MATCH (EAY131) trial, already underway. Press Release

May 26, 2016: The phase 2 precision medicine cancer trial, Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) is set to resume gene testing of patients on May 31, 2016, at 12:00 Noon Eastern Time. Press Release

September 4, 2015: The NCI-MATCH trial opens. The Cancer Letter

August 17, 2015: ECOG-ACRIN opens the phase 2 precision medicine cancer trial, National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131), the largest, most scientifically rigorous precision medicine trial in cancer to date, to cancer centers and community hospitals nationwide Press Release

June 5, 2015: NCI-MATCH to bring in public, and private funds, giving NCI a new urgent scientific agenda The Cancer Letter

June 5, 2015: Jim Doroshow on how NCI-MATCH is an example of what smart public-private partnerships can do The Cancer Letter

June 1, 2015: National Cancer Institute and ECOG-ACRIN announce the NCI-MATCH / EAY131 trial, a multi-arm phase 2 precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancer type Press Release